(Q39056372)

English

Real-life versus package insert: a post-marketing study on adverse-event rates of the virosomal hepatitis A vaccine Epaxal® in healthy travellers

scientific article published on 11 May 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Real-life versus package insert: a post-marketing study on adverse-event rates of the virosomal hepatitis A vaccine Epaxal® in healthy travellers (English)

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

1 reference

based on heuristic

inferred from title

hepatitis A vaccine

1 reference

based on heuristic

inferred from title

4

object named as

Blaise Genton

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

1

object named as

Christoph Hatz

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

author name string

Bernhard Beck

2

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Robert Steffen

3

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Valérie d'Acremont

5

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Louis Loutan

6

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Katharina Hartmann

7

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Christian Herzog

8

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

language of work or name

0 references

publication date

11 May 2011

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

29

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

31

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

5000-5006

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Spanish travelers to high-risk areas in the tropics: airport survey of travel health knowledge, attitudes, and practices in vaccination and malaria prevention

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.099

7 January 2021

Adverse events: the more you search, the more you find

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.099

7 January 2021

The Brighton Collaboration: addressing the need for standardized case definitions of adverse events following immunization (AEFI).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.099

7 January 2021

Brief communication: Better ways to question patients about adverse medical events: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.099

7 January 2021

A single vaccination with an inactivated hepatitis A liposome vaccine induces protective antibodies after only two weeks

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.099

7 January 2021

Inactivated virosome hepatitis A vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.099

7 January 2021

Safety, immunogenicity, and kinetics of the immune response to a single dose of virosome-formulated hepatitis A vaccine in Thais

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.099

7 January 2021

Immunogenicity and protectivity of a new liposomal hepatitis A vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.099

7 January 2021

Antibody titres after primary and booster vaccination of infants and young children with a virosomal hepatitis A vaccine (Epaxal®)

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.099

7 January 2021

Immunogenicity and safety of a virosomal hepatitis A vaccine (Epaxal) in the elderly.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.099

7 January 2021

Immunogenicity and safety of a pediatric dose of a virosome-adjuvanted hepatitis A vaccine: a controlled trial in children aged 1-16 years.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.099

7 January 2021

Immunogenicity and adverse effects of inactivated virosome versus alum-adsorbed hepatitis A vaccine: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.099

7 January 2021

Interchangeability and tolerability of a virosomal and an aluminum-adsorbed hepatitis A vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.099

7 January 2021

Rate, intensity, and duration of local reactions to a virosome-adjuvanted vs. an aluminium-adsorbed hepatitis A vaccine in UK travellers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.099

7 January 2021

Importance of attributable risk in monitoring adverse events after immunization: hepatitis B vaccination in children.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.099

7 January 2021

Detecting treatment emergent adverse events in clinical trials : a comparison of spontaneously reported and solicited collection methods

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.099

7 January 2021

The safety of valsartan: results of a postmarketing surveillance study on 12881 patients in England

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.099

7 January 2021

Virosomal hepatitis a vaccine: comparing intradermal and subcutaneous with intramuscular administration

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.099

7 January 2021

Travel vaccines and elderly persons: review of vaccines available in the United States.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.099

7 January 2021

Gender-based differences in drug prescription: relation to adverse drug reactions.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.099

7 January 2021

Stronger inflammatory/cytotoxic T-cell response in women identified by microarray analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.099

7 January 2021

Sexual dimorphism of humoral immunity with human vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.099

7 January 2021

Tolerance and immunogenicity of the simultaneous administration of virosome hepatitis A and yellow fever vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.099

7 January 2021

Safety and immunogenicity of concomitant versus nonconcomitant administration of hepatitis B, tetanus-diphtheria, and measles-mumps-rubella vaccines in healthy eleven- to twelve-year-olds.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.099

7 January 2021

Identifiers

10.1016/J.VACCINE.2011.04.099

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39056372&oldid=1806093528"